LucenceINSIGHT is an early detection tool that screens for signs of up to 50 different cancers using a simple blood test. This includes eye cancer, breast cancer, colon cancer, acute myeloid leukaemia (AML), and skin cancer. By harnessing the power of advanced genomics, and artificial intelligence, it can detect cancer at its earliest stages. Additionally, it can also predict the location of these cancer biomarkers through its advanced sequencing analysis, thereby prompting timely intervention and treatment.
Through a simple blood draw, the blood test detects cancer by analysing the DNA particles that are shed by tumours into the bloodstream. Additionally, with the use of advanced genomics technology, a specialised computer is then used to help identify genetic changes linked to cancer. It can also analyse the type, and stage of cancer, which ultimately aids doctors in outlining a more personalised treatment plan, apart from diagnosing, and monitoring cancer earlier, and more accurately.
Some of the benefits of LucenceINSIGHT multi-cancer early screening are:
LucenceINSIGHT is often recommended as an additional test on top of existing screening tools, such as an ultrasound for prostate cancer. It is also recommended when patients are presented with risk factors that increase their likelihood of developing cancer;
Globally, approximately 19 million new cases are recorded annually, with half of the cases resulting in late-stage deaths. In Singapore, cancer is the number one cause of death, and Singapore’s ageing population further increases the prevalence of cancer. Beyond that, approximately 78% of cancer deaths are from unscreened cancers such as liver, stomach, pancreas, and nasopharyngeal cancer.
Between 2017, and 2021, an average of 46 individuals were diagnosed with cancer, and 16 individuals lost their lives to cancer daily in Singapore. Additionally, 1 in 4 people is at risk of developing cancer in their lifetime due to a multitude of factors, such as genetics, and lifestyle. With such a high prevalence, early detection, and intervention are key to a more positive treatment outcome.
Additionally, early cancer screening can also help to:
Depending on the results, your next course of action would entail:
Positive results
Negative results
Similar to health screenings, it is recommended to schedule cancer screenings annually, or biannually. However, when it comes to cancer screening, the frequency will depend on your doctor’s discretion as it involves several factors such as type of cancer, stage, family history, and current health conditions.
If you are interested in scheduling an early cancer screening for yourself or your loved ones, then wait no more. Contact us today to book a slot, and speak with our doctors to stay a step ahead of this disease.
How accurate are the results from the LucenceINSIGHT multi-cancer early screening?
The LucenceINSIGHT multi-cancer early screening test offers an accuracy range between 81, and 99%.
How does the LucenceINSIGHT multi-cancer early screening differ from conventional screening tests?
The major difference between the two is that LucenceINSIGHT can detect up to 50 types of cancer from a single blood sample. Meanwhile, conventional screening tests typically target a specific type of cancer.
Are there any risks associated with the LucenceINSIGHT multi-cancer early screening that I should be aware of?
While there are no risks associated with the screening test, it is important to understand that the test is designed to screen for cancer, and not to diagnose it.
How soon will I obtain my results?
It takes approximately 12 to 18 days for you to receive your results. Once our doctors have received your results, our administrative staff will call you to schedule a consultation appointment, where our doctors will analyse, and explain the results to you.